Discoveries in the past decade have highlighted the potential of mRNA as a therapeutic
target for cancer. Specifically, RNA sequencing revealed that, in addition to gene mutations …

Major advances in our understanding of cancer pathogenesis and therapy have come from
efforts to catalog genomic alterations in cancer. A growing number of large-scale genomic …

While splicing changes caused by somatic mutations in SF3B1 are known, identifying full-
length isoform changes may better elucidate the functional consequences of these …

Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …

Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including
Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective …

Venetoclax is effective in relapsed patients with mantle cell lymphoma (MCL). Mechanisms
of resistance to venetoclax in MCL are poorly understood. We describe the clinical outcomes …

Lung cancer, including non-small cell lung carcinoma (NSCLC), is the most frequently
diagnosed cancer. It is also the leading cause of cancer-related mortality worldwide …

Precursor mRNA (pre-mRNA) splicing is an essential step in human gene expression and is
carried out by a large macromolecular machine called the spliceosome. Given the …

Transformation to aggressive disease histologies generates formidable clinical challenges
across cancers, but biological insights remain few. We modeled the genetic heterogeneity of …

Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is
incurable with standard therapies. The genetic drivers of this cancer have not been firmly …